Vaccines utilizing the membrane-bound carbohydrate antigens NeuGCGM3 and Muc1, have shown trends toward better clinical outcome and prolonged periods of no evidence of disease (NED) respectively, in advanced-stage assorted breast cancer36–38. This evidence concerns the gene MUC1 and neoplasm.